What is Lenvatinib?

Lenvatinib is a multi-receptor tyrosine kinase inhibitor that exhibits potent anti-angiogenic properties and is indicated for monotherapy or combination therapy in certain malignancies. The U.S. Food and Drug Administration (FDA) approved lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and advanced endometrial cancer (EC). Lenvatinib can be used as a single drug or in combination with other drugs.

Lenvatinib inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs involved in pathogenic angiogenesis, tumor growth, and cancer progression, as well as their normal cellular functions, including the fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).